Targeting legumain as a novel therapeutic strategy in cancers

(Bentham Science Publishers) This review will be the first to summarize the expression of legumain (LGMN) in common cancers, as well as its roles in tumourigenesis and metastasis. This review also discusses the current developments and future prospects of targeting LGMN through the development of DNA vaccines, azo-peptides, small molecule inhibitors and LGMN activated prodrugs, highlighting the potential of LGMN as a target for cancer therapeutics.